Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-11-07
2006-11-07
Zara, Jane (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S006120, C435S091100, C435S458000
Reexamination Certificate
active
07132529
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6030837 (2000-02-01), McKay et al.
patent: 6077672 (2000-06-01), Monia et al.
patent: 6261840 (2001-07-01), Cowsert et al.
patent: 2002/0151018 (2002-10-01), Prouty et al.
patent: 2003/0083282 (2003-05-01), Crooke et al.
patent: 0 238 198 (1987-08-01), None
patent: WO 96/18736 (1996-06-01), None
patent: WO 99/63979 (1999-12-01), None
patent: WO 99/67378 (1999-12-01), None
patent: WO 00/09754 (2000-02-01), None
Agrawal et al. Antisense Therapeutics: is it as simple as complementary base recognition? Molecular Medicine Today, Feb. 2000, vol. 6, pp. 72-81.
Green et al. Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease. J Am. Coll. Surg. vol. 191, No. 1, Jul. 2000, pp. 93-105.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells 2000; 18:307-319.
Branch, A.D. A good antisense molecule is hard to find. TIBS Feb. 23, 1998, pp. 45-50.
Milner et al. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnology, vol. 15, Jun. 1997, pp. 537-541.
Opalinska et al. Nature Reviews Drug Discovery, 2002, vol. 1, p. 503-514.
Benéet al., “Cloning and Characterization of the Human Stearoyl-CoA Desaturase Gene Promoter:Transcriptional Activation by Sterol Regulatory Element Binding Protein and Repression by Polyunsaturated Fatty Acids and Cholesterol”, Biochemistry and Biophysical Research Communications 2001 284:1194-1198.
Diot et al., “Stearoyl-CoA Desaturase 1 Coding Sequences and Antisense RNA Affect Lipid Secretion in Transfected Chicken LMH Hepatoma Cells”, Archives of Biochemistry and Biophysics 2000 380 (2) :243-250.
Jones et al., “Adipose tissue stearoyl-CoA desaturase mRNA is increased by obesity and decreased by polyunsaturated fatty acids”, Am. J. Physiol. (Endocrinol. Metab. 34) :E44-E49 1996.
Kim et al., “Differential regualtion of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes”, J. Lipid Res. 2000 41:1310-1316.
Li et al., “Partial Characterization of A cDNA for Human Stearoyl-CoA Desaturase and Changes in its mRNA Expression in Some Normal and Malignant Tissues”, Int. J. Cancer 1994 57:348-352.
Ntambi J. M., “The Regulation of Stearoyl-CoA Desaturase (SCD)”, Prog. Lipid Res. 1995 34 (2) :139-150.
Ntambi J.M., “Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol”, J. Lipid Res. 1999 40:1549-1558.
Sessler et al., “Regulation of Stearoyl-C-A Desaturase 1 mRNA Stability by Polyunsaturated Fatty Acids in 3T3-L1 Adipocytes”, J. Biol. Chem. 1996 271 (47) :29854-29858.
Singh et al., “Differential Effects of Rexinoids and Thiazolidinediones on Matabolic Gene Expression in Diabetic Rodents”, Mol. Pharmacol 2001 59:765-773.
Zhang et al., “Human stearoyl-CoA desaturase:alternative transcripts generated from a single gene by usage of tandem polyadenylation sites”, Biochem. J. 1999 340:255-264.
Zhang et al., “Isolation and characterization of the human stearoyl-CoA desaturase gene promoter:requirement of a conserved CCAAT cis-element”, Biochem. J. 2001 357:183-193.
Taylor, Margaret F., et al., “Antisense Oligonucleotides: A Systematic High-Throughput Approach to Target Validation and Gene Function Determination,”DDT, 4(12): 562-567 (1999).
Crooke Rosanne M.
Graham Mark J.
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Isis Pharmaceuticals , Inc.
Vivlemore Tracy
Ward Donna T.
LandOfFree
Antisense modulation of stearoyl-CoA desaturase expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of stearoyl-CoA desaturase expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of stearoyl-CoA desaturase expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665460